{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:10:36Z","timestamp":1794543036860,"version":"4.9.1"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82004339"],"award-info":[{"award-number":["82004339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973498"],"award-info":[{"award-number":["81973498"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104508"],"award-info":[{"award-number":["82104508"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010097","name":"China Association for Science and Technology","doi-asserted-by":"publisher","award":["2021-QNRC2-B17"],"award-info":[{"award-number":["2021-QNRC2-B17"]}],"id":[{"id":"10.13039\/100010097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018541","name":"Science Fund for Distinguished Young Scholars of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231528"],"award-info":[{"award-number":["BK20231528"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231380"],"award-info":[{"award-number":["BK20231380"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.critrevonc.2024.104353","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T22:05:45Z","timestamp":1712959545000},"page":"104353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-8270","authenticated-orcid":false,"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2024.104353_bib1","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","article-title":"Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity","volume":"97","author":"Alberti","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2024.104353_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuro.2016.05.004","article-title":"Inhibition of the neuronal NF\u03baB pathway attenuates bortezomib-induced neuropathy in a mouse model","volume":"55","author":"Al\u00e9","year":"2016","journal-title":"Neurotoxicology"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12640-014-9514-8","article-title":"Toxic effects of bortezomib on primary sensory neurons and Schwann cells of adult mice","volume":"27","author":"Al\u00e9","year":"2015","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.critrevonc.2024.104353_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.expneurol.2013.12.020","article-title":"Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model","volume":"253","author":"Al\u00e9","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuro.2014.02.001","article-title":"Neurotoxicity induced by antineoplastic proteasome inhibitors","volume":"43","author":"Al\u00e9","year":"2014","journal-title":"NeuroToxicology"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib6","first-page":"696","article-title":"Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma","volume":"18","author":"Allegra","year":"2022","journal-title":"Arch. Med Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib7","first-page":"2734","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical cancer research: an official","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib8","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: an update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib9","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104353_bib10","first-page":"1361","article-title":"Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings","volume":"90","author":"Argyriou","year":"2019","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104353_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1744806917714693","article-title":"Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy","volume":"13","author":"Aromolaran","year":"2017","journal-title":"Mol. Pain."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib13","first-page":"2384","article-title":"Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues","volume":"18","author":"Bae","year":"2021","journal-title":"Neurother.\u00a0J. Am. Soc. Exp. Neurother."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.558","article-title":"Chemotherapy-induced neuropathies-a growing problem for patients and health care providers","volume":"7","author":"Banach","year":"2017","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaneurol.2020.2590","article-title":"Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial","volume":"78","author":"Barohn","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146621","article-title":"Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy","volume":"1730","author":"Bechakra","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.critrevonc.2024.104353_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918797042","article-title":"Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain","volume":"14","author":"Bechakra","year":"2018","journal-title":"Mol. Pain."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib18","first-page":"2411","article-title":"Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice","volume":"24","author":"Beijers","year":"2016","journal-title":"Support. Care Cancer\u00a0Off. J. Multinatl. Assoc. Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib19","first-page":"421","article-title":"Bortezomib-induced painful neuropathy in patients with multiple myeloma","volume":"17","author":"Bilinska","year":"2013","journal-title":"Conte Oncol. (Pozn. )"},{"key":"10.1016\/j.critrevonc.2024.104353_bib20","article-title":"Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain","volume":"12","author":"Bloomingdale","year":"2021","journal-title":"Front Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104353_bib21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/14740338.2017.1344212","article-title":"Safety of ixazomib for the treatment of multiple myeloma","volume":"16","author":"Bonnet","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/fcp.12617","article-title":"An overview of ongoing clinical trials assessing pharmacological therapeutic strategies to manage chemotherapy-induced peripheral neuropathy, based on preclinical studies in rodent models","volume":"35","author":"Bouchenaki","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104353_bib23","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00280-014-2550-5","volume":"74","author":"Callander","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072995","article-title":"Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse","volume":"8","author":"Carozzi","year":"2013","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J. Pain."},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2024.104353_bib29","first-page":"S6","article-title":"Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue","volume":"24","author":"Cavaletti","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061370","article-title":"Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy","volume":"12","author":"Cavaletti","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib32","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","article-title":"Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment","volume":"270","author":"Cebulla","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12974-018-1327-x","article-title":"Reduction of SIRT1 epigenetically upregulates NALP1 expression and contributes to neuropathic pain induced by chemotherapeutic drug bortezomib","volume":"15","author":"Chen","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib34","first-page":"2669","article-title":"Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"22","author":"Cho","year":"2014","journal-title":"Support. Care Cancer: Off. J. Multinatl. Assoc. Support. Care Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2024.104353_bib35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11655-020-3196-2","article-title":"Effect Evaluation of Strychnos nux-vomica L. with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients: A Self-Controlled Clinical Trial","volume":"27","author":"Dai","year":"2021","journal-title":"Chin. J. Integr. Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000491662","article-title":"Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib","volume":"48","author":"Duan","year":"2018","journal-title":"Cell. Physiol. Biochem.: Int. J. Exp. Cell. Physiol., Biochem., Pharmacol."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104353_bib41","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1111\/bph.14063","article-title":"Characterization of a rat model of bortezomib-induced painful neuropathy","volume":"174","author":"Duggett","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"10068","key":"10.1016\/j.critrevonc.2024.104353_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104353_bib43","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00384-018-3104-9","article-title":"Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study","volume":"33","author":"El-Fatatry","year":"2018","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.critrevonc.2024.104353_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113519","article-title":"Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back","volume":"336","author":"Geisler","year":"2021","journal-title":"Exp. Neurol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104353_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129920","article-title":"Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program","volume":"4","author":"Geisler","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2024.104353_bib46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuropharm.2014.08.004","article-title":"Spinal administration of mGluR5 antagonist prevents the onset of bortezomib induced neuropathic pain in rat","volume":"86","author":"Ghelardini","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.critrevonc.2024.104353_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8143754","article-title":"The Actions and Mechanisms of P2\u00d77R and p38 MAPK Activation in Mediating Bortezomib-Induced Neuropathic Pain","volume":"2020","author":"Guo","year":"2020","journal-title":"BioMed. Res. Int."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib48","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/j.pain.0000000000000862","article-title":"Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats","volume":"158","author":"Hamity","year":"2017","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib49","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12185-012-1224-5","article-title":"Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy","volume":"96","author":"Hashimoto","year":"2012","journal-title":"Int J. Hematol."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104353_bib50","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104353_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073734","article-title":"Specific Attenuation of Purinergic Signaling during Bortezomib-Induced Peripheral Neuropathy In Vitro","volume":"23","author":"Holzer","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5414\/CP202714","article-title":"Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis","volume":"55","author":"Hu","year":"2017","journal-title":"Int J. Clin. Pharm. Ther."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104353_bib53","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.1158\/1078-0432.CCR-18-2152","article-title":"Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy","volume":"25","author":"Hu","year":"2019","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib54","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1172\/JCI136796","article-title":"Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice","volume":"130","author":"Huang","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104353_bib55","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.21873\/anticanres.14357","article-title":"Protection of Bortezomib-induced Neurotoxicity by Antioxidants","volume":"40","author":"Iijima","year":"2020","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.critrevonc.2024.104353_bib57","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","article-title":"The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1","volume":"289","author":"Janes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2024.104353_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101502","article-title":"Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib","volume":"32","author":"Jannuzzi","year":"2020","journal-title":"Redox Biol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib59","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","article-title":"Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis","volume":"21","author":"Kanbayashi","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104353_bib60","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.clinph.2017.04.009","article-title":"Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer","volume":"128","author":"Kandula","year":"2017","journal-title":"Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34507-3","article-title":"Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib","volume":"8","author":"Karademir","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jphs.2018.06.008","article-title":"Dimethyl fumarate ameliorates chemotherapy agent-induced neurotoxicity in vitro","volume":"137","author":"Kawashiri","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104353_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920936502","volume":"16","author":"Kober","year":"2020","journal-title":"Mol. Pain."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jnnp-2020-323999","article-title":"Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis","volume":"92","author":"Lambru","year":"2021","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.critrevonc.2024.104353_bib65","first-page":"1159","volume":"334","author":"Lauria","year":"2007"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104353_bib66","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1007\/s00415-020-09988-w","article-title":"Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review","volume":"267","author":"Lazzarin","year":"2020","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib67","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2024.104353_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: A mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104353_bib70","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40263-020-00760-2","article-title":"Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study","volume":"34","author":"Lipone","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.critrevonc.2024.104353_bib71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbi.2015.11.004","article-title":"Upregulation of CCL2 via ATF3\/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy","volume":"53","author":"Liu","year":"2016","journal-title":"Brain, Behav., Immun."},{"key":"10.1016\/j.critrevonc.2024.104353_bib72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.expneurol.2018.01.011","article-title":"Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib","volume":"302","author":"Liu","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib73","doi-asserted-by":"crossref","first-page":"845","DOI":"10.33549\/physiolres.934015","article-title":"Inhibition of TRPA1 and IL-6 signal alleviates neuropathic pain following chemotherapeutic bortezomib","author":"Liu","year":"2019","journal-title":"Physiol. Res. 68(5"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104353_bib74","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s11064-022-03571-7","article-title":"Metformin Relieves Bortezomib-Induced Neuropathic Pain by Regulating AMPKa2-Mediated Autophagy in the Spinal Dorsal Horn","volume":"47","author":"Liu","year":"2022","journal-title":"Neurochem Res"},{"key":"10.1016\/j.critrevonc.2024.104353_bib75","first-page":"6","article-title":"Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy","author":"LoCoco","year":"2017","journal-title":"eLife"},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104353_bib76","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052431","article-title":"Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development","volume":"23","author":"Luczkowska","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052431","article-title":"Bortezomib-Induced Epigenetic Alterations in Nerve Cells: Focus on the Mechanisms Contributing to the Peripheral Neuropathy Development","volume":"23","author":"\u0141uczkowska","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104353_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/1744806919837429","article-title":"Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy","volume":"15","author":"Ludman","year":"2019","journal-title":"Mol. Pain."},{"key":"10.1016\/j.critrevonc.2024.104353_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/1744806919850043","article-title":"Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy","volume":"15","author":"Ludman","year":"2019","journal-title":"Mol. Pain."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib81","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1111\/cas.14178","article-title":"Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma","volume":"110","author":"Maekawa","year":"2019","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104353_bib82","first-page":"4223","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Maih\u00f6fner","year":"2021","journal-title":"Support. Care Cancer\u00a0Off. J. Multinatl. Assoc. Support. Care Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib83","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1177\/1534735418803758","article-title":"Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and \u03b1-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data","volume":"17","author":"Maschio","year":"2018","journal-title":"Integr. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib84","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3892\/ol.2022.13228","article-title":"Transient receptor potential channels in multiple myeloma","volume":"23","author":"Meng","year":"2022","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib85","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/toxics3030294","article-title":"An overview of Bortezomib-induced neurotoxicity","volume":"3","author":"Meregalli","year":"2015","journal-title":"Toxics"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib86","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/cc.27476","article-title":"Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy","volume":"13","author":"Meregalli","year":"2014","journal-title":"Cell Cycle"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104353_bib87","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/cancers13195013","article-title":"Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models","volume":"13","author":"Meregalli","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib88","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12974-018-1270-x","article-title":"High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats","volume":"15","author":"Meregalli","year":"2018","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib89","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104353_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12840","article-title":"Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS","volume":"7","author":"Miyake","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib91","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1078155218788706","article-title":"Incidence and management of adverse events associated with panobinostat in the treatment of relapsed\/refractory multiple myeloma","volume":"25","author":"Moore","year":"2019","journal-title":"J. Oncol. Pharm. Pract.: Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib92","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clml.2019.08.012","article-title":"Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma","volume":"20","author":"Moore","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2024.104353_bib93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-pharmtox-010617-052832","article-title":"TRP Channels as Potential Drug Targets","volume":"58","author":"Moran","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104353_bib94","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-019-1461-0","article-title":"Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy","volume":"16","author":"Moschetti","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.critrevonc.2024.104353_bib96","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3389\/fimmu.2020.02119","article-title":"Prokineticin Receptor Inhibition With PC1 Protects Mouse Primary Sensory Neurons From Neurotoxic Effects of Chemotherapeutic Drugs in vitro","volume":"11","author":"Moschetti","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib97","article-title":"Blocking TRPA1 in Respiratory Disorders: Does It Hold a Promise?","volume":"9","author":"Mukhopadhyay","year":"2016","journal-title":"Pharm. (Basel, Switz. )"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib98","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00424-012-1158-z","article-title":"The transient receptor potential channel TRPA1: from gene to pathophysiology","volume":"464","author":"Nilius","year":"2012","journal-title":"Pflug. Arch."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104353_bib99","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092540","article-title":"Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects","volume":"12","author":"Pancheri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"36)","key":"10.1016\/j.critrevonc.2024.104353_bib101","first-page":"3401","article-title":"Calcium-dependent proteasome activation is required for axonal neurofilament degradation","volume":"8","author":"Park","year":"2013","journal-title":"Neural Regen. Res"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2024.104353_bib102","first-page":"S13","article-title":"Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity","volume":"24","author":"Park","year":"2019","journal-title":"J. Peripher. Nerv. Syst.: JPNS"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104353_bib103","first-page":"2813","article-title":"Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib","volume":"23","author":"Peng","year":"2015","journal-title":"Support. Care Cancer: Off. J. Multinatl. Assoc. Support. Care Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib104","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012685118","article-title":"Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy","volume":"118","author":"Pero","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104353_bib106","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2014.11.009","article-title":"Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy","volume":"285","author":"Robinson","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.critrevonc.2024.104353_bib108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brainres.2014.06.013","article-title":"Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy","volume":"1574","author":"Robinson","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.critrevonc.2024.104353_bib109","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuroscience.2014.05.051","article-title":"Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat","volume":"274","author":"Robinson","year":"2014","journal-title":"Neuroscience"},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104353_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111913","article-title":"Interplay between Prokineticins and Histone Demethylase KDM6A in a Murine Model of Bortezomib-Induced Neuropathy","volume":"22","author":"Rullo","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib111","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/jgh.15765","article-title":"Efficacy of amitriptyline in pediatric functional abdominal pain disorders: A randomized placebo-controlled trial","volume":"37","author":"Seetharaman","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front Pharm."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104353_bib113","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/glia.21065","article-title":"Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy","volume":"58","author":"Shin","year":"2010","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA\u00a0Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib115","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1177\/1078155220904153","article-title":"Bortezomib-induced motor neuropathy: a case report","volume":"26","author":"Singh","year":"2020","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104353_bib116","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049358","article-title":"Bortezomib-induced neurotoxicity in human neurons is the consequence of nicotinamide adenine dinucleotide depletion","volume":"15","author":"Snavely","year":"2022","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.critrevonc.2024.104353_bib117","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719839025","article-title":"Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis","volume":"10","author":"Song","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104353_bib118","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol.\u00a0Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-023-05624-1","article-title":"Bortezomib-induced neuropathy is in part mediated by the sensitization of TRPV1 channels","volume":"6","author":"Sprague","year":"2023","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib120","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42003-023-05624-1","article-title":"Bortezomib-induced neuropathy is in part mediated by the sensitization of TRPV1 channels","volume":"6","author":"Sprague","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10880","article-title":"A phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2024.104353_bib122","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuro.2013.09.001","article-title":"Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons","volume":"39","author":"Staff","year":"2013","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib123","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/cts.12915","article-title":"Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy","volume":"14","author":"Stage","year":"2021","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib124","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib125","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/j.pain.0000000000001697","article-title":"Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents","volume":"161","author":"Stockstill","year":"2020","journal-title":"Pain"},{"issue":"30","key":"10.1016\/j.critrevonc.2024.104353_bib127","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.2217\/fon-2018-0040","article-title":"The role of carfilzomib in treatment of newly diagnosed multiple myeloma","volume":"14","author":"Strifler","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib128","doi-asserted-by":"crossref","DOI":"10.1200\/OP.22.00781","article-title":"Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction","author":"Sun","year":"2023","journal-title":"JCO Oncol. Pr."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11064-022-03741-7","article-title":"MiR-672-5p-Mediated upregulation of REEP6 in spinal dorsal horn participates in Bortezomib-induced neuropathic pain in rats","volume":"48","author":"Sun","year":"2023","journal-title":"Neurochem Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib130","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104353_bib131","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1248\/bpb.b22-00861","article-title":"Inhibitors of the mechanistic target of Rapamycin can ameliorate bortezomib-induced peripheral neuropathy","volume":"46","author":"Suzuki","year":"2023","journal-title":"Biol. Pharm. Bull."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104353_bib132","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71138-z","article-title":"Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro","volume":"10","author":"Tak\u00e1cs","year":"2020","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104353_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143411","article-title":"Emerging Perspectives on Pain Management by Modulation of TRP Channels and ANO1","volume":"20","author":"Takayama","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib135","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib136","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CND.0000000000000077","article-title":"Bortezomib-associated demyelinating neuropathy--clinical and pathologic features","volume":"16","author":"Thawani","year":"2015","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.critrevonc.2024.104353_bib137","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2018.12.003","article-title":"Critical role of Ca(v)3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice.","volume":"413","author":"Tomita","year":"2019","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib138","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bph.13652","article-title":"The peptide Ph\u03b11\u03b2, from spider venom, acts as a TRPA1 channel antagonist with antinociceptive effects in mice","volume":"174","author":"Tonello","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib139","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1158\/0008-5472.CAN-12-4370","article-title":"Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade","volume":"73","author":"Trevisan","year":"2013","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104353_bib140","first-page":"1239","article-title":"Trametinib suppresses chemotherapy-induced cold and mechanical allodynia via inhibition of extracellular-regulated protein kinase 1\/2 activation","volume":"8","author":"Tsubaki","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib141","doi-asserted-by":"crossref","DOI":"10.1177\/1010428318808670","article-title":"Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C\/extracellular signal-regulated kinase pathway","volume":"40","author":"Tsubaki","year":"2018","journal-title":"Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104353_bib142","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/10428194.2021.1992758","article-title":"Foot drop in patients treated with bortezomib - a case series and review of the literature","volume":"63","author":"Vaxman","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2024.104353_bib143","first-page":"S52","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib144","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CAD.0000000000001005","article-title":"Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience","volume":"32","author":"Velasco","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1529-8027.2010.00248.x","article-title":"Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"15","author":"Velasco","year":"2010","journal-title":"J. Peripher. Nerv. Syst.: JPNS"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104353_bib146","doi-asserted-by":"crossref","first-page":"453","DOI":"10.36076\/ppj.2021.24.453","article-title":"Treatment Impact on Patient-Reported Outcomes in Peripheral Neuropathic Pain: Comparing Single Intervention With Topical High-Concentration Capsaicin to Daily Oral Pregabalin","volume":"24","author":"Viel","year":"2021","journal-title":"Pain. Physician"},{"key":"10.1016\/j.critrevonc.2024.104353_bib147","article-title":"The Effect of Schwann Cells\/Schwann Cell-Like Cells on Cell Therapy for Peripheral Neuropathy","volume":"16","author":"Wang","year":"2022","journal-title":"Front Cell Neurosci."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104353_bib148","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6605954","article-title":"Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy","volume":"103","author":"Watanabe","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104353_bib149","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00204-023-03468-6","article-title":"Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity","volume":"97","author":"Wu","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.neuropharm.2017.06.027","article-title":"Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord","volume":"123","author":"Xie","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.critrevonc.2024.104353_bib151","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.neuropharm.2017.06.027","article-title":"Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord","volume":"123","author":"Xie","year":"2017","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020888","article-title":"Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib153","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jphs.2015.08.006","article-title":"Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats","volume":"129","author":"Yamamoto","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104353_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112068","article-title":"The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy","volume":"142","author":"Yan","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104353_bib155","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/00365513.2021.1986857","article-title":"Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study","volume":"81","author":"Yang","year":"2021","journal-title":"Scand. J. Clin. Lab Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib156","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2024.104353_bib157","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3389\/fphar.2018.00999","article-title":"Triptriolide Alleviates Lipopolysaccharide-Induced Liver Injury by Nrf2 and NF-kappaB Signaling Pathways.","volume":"9","author":"Yang","year":"2018","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib158","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1568009618666181003170027","article-title":"The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy","volume":"19","author":"Yin","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2024.104353_bib159","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbi.2014.01.020","article-title":"TNF-\u03b1-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy","volume":"38","author":"Zhang","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib160","first-page":"480","article-title":"Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin]","volume":"25","author":"Zhang","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104353_bib161","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.critrevonc.2024.104353_bib162","doi-asserted-by":"crossref","DOI":"10.1177\/1744806919863292","article-title":"GATA3-dependent epigenetic upregulation of CCL21 is involved in the development of neuropathic pain induced by bortezomib","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Pain."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104353_bib163","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1534735418788667","article-title":"Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain","volume":"17","author":"Zhi","year":"2018","journal-title":"Integr. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104353_bib164","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-023-00490-9","article-title":"Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1","volume":"11","author":"Zhou","year":"2023","journal-title":"Biomark. Res"},{"key":"10.1016\/j.critrevonc.2024.104353_bib165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1756-8722-5-67","article-title":"Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naive or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial","volume":"5","author":"Zinzani","year":"2012","journal-title":"J. Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:22:33Z","timestamp":1778581353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":165,"alternative-id":["S1040842824000969"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104353","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104353"}}